Pharmaceutical

Risk adjusted net present value: What is the current valuation of AstraZeneca’s Saruparib?

Saruparib is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Metastatic Prostate Cancer.

Mar 13, 2024 - 18:29
Saruparib is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Metastatic Prostate Cancer.
Read the original article

Tags:

Previous Article

Eli Lilly’s Lebrikizumab Shows Promise in Eczema Treatment for Skin of Color

Next Article

Risk adjusted net present value: What is the current valuation of AstraZeneca’s ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Listen: Messy PBM conflicts, debatable vaccines, & the future of flu season

Listen: Messy PBM conflicts, debatable vaccines, & the ...

Jun 22, 2023

What health policies could hitch a ride on a spending bill?

What health policies could hitch a ride on a spending b...

Nov 15, 2023

FDA approves Madrigal’s Rezdiffra as the first NASH therapy

FDA approves Madrigal’s Rezdiffra as the first NASH the...

Mar 16, 2024